Related references
Note: Only part of the references are listed.Genetic evidence that SOST inhibits WNT signaling in the limb
Nicole M. Collette et al.
DEVELOPMENTAL BIOLOGY (2010)
Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo
M. R. Forwood
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Prostaglandins in bone: bad cop, good cop?
Katherine A. Blackwell et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Discovery of CP-533536: An EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation
Kimberly O. Cameron et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures
Tomoko Minamizaki et al.
BONE (2009)
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway
Nobuhiro Kamiya et al.
DEVELOPMENT (2008)
Microarray analysis of thapsigargin - induced stress to the endoplasmic reticulum of mouse osteoblasts
Kazunori Hamamura et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2008)
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength
Xiaodong Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
Charles A. O'Brien et al.
PLOS ONE (2008)
Control of the SOST bone enhancer by PTH using MEF2 transcription factors
Olivier Leupin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Hypoxia regulates PGE2 release and EN receptor expression in osteoblastic cells
Christina M. Lee et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Prostaglandin E receptors
Yukihiko Sugimoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
New technologies for the enhancement of skeletal repair
T. William Axelrad et al.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED (2007)
LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST
Mikhail V. Semenov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity
Debra L. Ellies et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment
Kimihiko Sawakami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Wnt signaling and osteoblastogenesis
Peter V. N. Bodine et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2006)
Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass
Frederic Morvan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis
PVN Bodine et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
T Bellido et al.
ENDOCRINOLOGY (2005)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
M Semënov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
GG Loots et al.
GENOME RESEARCH (2005)
Essential role of β-catenin in postnatal bone acquisition
SL Holmen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling
XF Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6
SL Holmen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice
PVN Bodine et al.
MOLECULAR ENDOCRINOLOGY (2004)
Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity
N Kusu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
An EP2 receptor-selective prostaglandin E2 agonist induces bone healing
VM Paralkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor
X Billot et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
A novel, non-prostanoid EP2 receptor-selective prostaglandin E-2 agonist stimulates local bone formation and enhances fracture healing
M Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Cyclo-oxygenase 2 function is essential for bone fracture healing
AM Simon et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor
M Kato et al.
JOURNAL OF CELL BIOLOGY (2002)
Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway
S Wadhwa et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait
RD Little et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development
YQ Gong et al.
CELL (2001)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
Wnt/β-catenin signaling
T Akiyama
CYTOKINE & GROWTH FACTOR REVIEWS (2000)
MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type
H Wu et al.
EMBO JOURNAL (2000)
Ca2+-dependent gene expression mediated by MEF2 transcription factors
F Blaeser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
